pharmaceutical investing Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial
pharmaceutical investing Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin) in combination with KEYTRUDA (pembrolizumab) for Triple Negative Breast Cancer
Syntholene Energy Corp. Announces Engagement of DS Market Solutions Inc. for Liquidity Services and Emerging Markets Consulting for Communications and Marketing Services
Skyharbour Announces Drilling Underway and Renewed Permit at the High-Grade Moore Lake Uranium Project, Saskatchewan
